Browse LRGUK

Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasmic vesicle, secretory vesicle, acrosome Cytoplasm, cytoskeleton Cytoplasm, cytoskeleton, cilium basal body Note=Localizes to the acrosome and acroplaxome in round spermatids. Localizes to the manchette during spermiogenesis. Also found in the basal body of elongating spermatids, and in primary cilia of somatic cells.
Domain PF00625 Guanylate kinase
Function

Involved in multiple aspects of sperm assembly including acrosome attachment, shaping of the sperm head and in the early aspects of axoneme development. Not essential for primary cilium biogenesis.

> Gene Ontology
 
Biological Process GO:0000226 microtubule cytoskeleton organization
GO:0001578 microtubule bundle formation
GO:0007283 spermatogenesis
GO:0010927 cellular component assembly involved in morphogenesis
GO:0030031 cell projection assembly
GO:0035082 axoneme assembly
GO:0042384 cilium assembly
GO:0044782 cilium organization
GO:0048232 male gamete generation
GO:0060271 cilium morphogenesis
Molecular Function -
Cellular Component GO:0001669 acrosomal vesicle
GO:0002177 manchette
GO:0030141 secretory granule
GO:0097223 sperm part
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LRGUK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LRGUK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LRGUK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0670.895
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1890.825
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2480.725
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.7860.0306
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5120.656
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.1310.429
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0330.955
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4950.558
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7390.405
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1920.683
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.380.559
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0790.597
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LRGUK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.18.22.90.699
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.16.84.30.673
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRGUK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRGUK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRGUK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRGUK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LRGUK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LRGUK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLRGUK
Nameleucine-rich repeats and guanylate kinase domain containing
Aliases FLJ32786; CFAP246; Leucine-rich repeat and guanylate kinase domain-containing protein
Chromosomal Location7q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LRGUK collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.